Cipla Limited (BOM:500087)
India · Delayed Price · Currency is INR | Market Cap | 1.14T -6.4% |
| Revenue (ttm) | 277.12B +1.6% |
| Net Income | 38.79B -26.4% |
| EPS | 48.00 -26.4% |
| Shares Out | n/a |
| PE Ratio | 29.44 |
| Forward PE | 27.50 |
| Dividend | 13.00 (0.93%) |
| Ex-Dividend Date | Jun 5, 2026 |
| Volume | 266,049 |
| Open | 1,427.95 |
| Previous Close | 1,413.50 |
| Day's Range | 1,410.00 - 1,427.95 |
| 52-Week Range | 1,165.55 - 1,672.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 1,459.57 (+3.0%) |
| Earnings Date | May 13, 2026 |
About Cipla
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obe... [Read more]
Financial Performance
In fiscal year 2026, Cipla's revenue was 277.12 billion, an increase of 1.63% compared to the previous year's 272.67 billion. Earnings were 38.79 billion, a decrease of -26.43%.
Financial StatementsNews
Bharti Airtel, Cipla & more: Top stocks to watch on May 18
Jefferies raised Bharti Airtel's target price to Rs 2,350 on strong Q4FY26 performance, while JP Morgan upgraded Cipla to overweight citing improved earnings visibility and attractive valuations. Morg...
Pharma sector stocks today, May 14: Cipla jumps 7.15%, Zydus Lifesciences rises 4.01%, Strides Pharma up 2.20%
Pharmaceutical stocks opened strongly on May 14 2026 during the early morning trading session. The sector witnessed broad-based buying interest with most stocks trading in the green. The BSE Healthcar...
Cipla Ltd (BOM:500087) Full Year 2026 Earnings Call Highlights: Strong India Growth and ...
Cipla Ltd (BOM:500087) Full Year 2026 Earnings Call Highlights: Strong India Growth and Strategic AI Initiatives
Full Year 2026 Cipla Ltd Earnings Call Transcript
Full Year 2026 Cipla Ltd Earnings Call Transcript
Cipla Transcript: Q4 25/26
Q4 FY26 saw robust growth across all geographies, with India and North America delivering strong results and key product launches. FY27 guidance targets double-digit India growth and a $1B U.S. run rate, with EBITDA margins of 18.5%-20% and continued R&D and AI investments.
Cipla Quarterly report: Q4 2026
Cipla has published its Q4 2026 quarterly earnings report on May 13, 2026.
Cipla Slides: Q4 2026
Cipla has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
Cipla Transcript: Q4 25/26
Q4 and FY26 saw robust growth across all geographies, with India and North America leading performance and key regulatory approvals boosting the pipeline. FY27 guidance targets double-digit India growth, a $1B U.S. run rate, and 18.5%-20% EBITDA margin, with risks from geopolitical factors.
Cipla Quarterly report: Q4 2026
Cipla has published its Q4 2026 quarterly earnings report on May 13, 2026.
Cipla Slides: Q4 2026
Cipla has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 13, 2026.
CIPLA Reports 54.6% Drop in Q4 Net Profit Amid Rising Costs
CIPLA Reports 54.6% Drop in Q4 Net Profit Amid Rising Costs
Cipla appoints Sushrut Kulkarni as Global Chief for Integrated Product Development
Cipla has announced the appointment of Mr Sushrut Kulkarni as President & Global Chief – Integrated Product Development (IPD), effective from 18th May 2026. This strategic appointment was approved dur...
Cipla reports Rs 28,163 crore revenue for FY26 with robust growth in India and Africa
Cipla Limited announced its audited consolidated financial results for the quarter ended 31st March 2026, reporting a significant annual revenue of ₹28,163 crore for FY26. The company achieved double-...
Cipla declares ₹13 dividend despite Q4 profit crash — what went wrong and should investors worry?
Cipla Limited's Q4 FY26 results landed with a thud on May 13 — net profit down 55%, EBITDA margin more than halved, and a miss against analyst estimates so sharp…
Cipla Q4 Results: Profit falls 55% on a YoY basis, margin contracts sharply
Cipla Ltd. reported a decline in consolidated profitability for the quarter ended March 31, 2026, as operating margins weakened amid higher expenses. Revenue from operations during Q4 FY26 stood at…
Cohance Lifesciences Hits 20% Upper Circuit After Appointing Former Cipla CEO Umang Vohra as Chairman and Group CEO
Shares of Cohance Lifesciences hit the 20% upper circuit, surging ₹72 to ₹432.10 on the NSE as of 9:38 AM IST on Monday, April 27, after the company announced the…
Cipla faces $100 million revenue risk as USFDA alert delays restart beyond FY27, says Macquarie
Cipla may face a significant setback to its US growth trajectory after a regulatory action impacted supplies of a key product, with brokerage firm Macquarie flagging a potential revenue risk…
Cipla Shares Fall 3% as Partner Unit Gets FDA Import Alert, Lanreotide Revenue at Risk
Cipla shares dropped 2.93% or ₹38.20 to ₹1,267.70 on the NSE as of 9:25 AM IST on April 24, touching an intraday low of ₹1,254.10 in early trade, after it…
Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup
A busy morning for broker calls with Infosys drawing the most divided analyst opinion after its Q4 FY26 results, Dr Reddy's receiving back-to-back downgrades on the Semaglutide opportunity, Cipla gett...
Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more
Indian equity benchmarks ended lower on Thursday, April 23, 2026, with the NIFTY 50 closing at 24,173.05, down 205.05 points (-0.84%). Despite the broader market weakness, select stocks managed to…
Cipla gets USFDA nod for first AB-rated generic of Ventolin HFA
Cipla Limited on April 23 announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Albuterol…
Cipla receives USFDA approval for first AB-rated generic of Ventolin HFA
Cipla Limited has announced that its wholly owned subsidiary, Cipla USA Inc., has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug…
Pharma sector stocks today, April 22: Natco Pharma up 1.4%, Lupin falls 1.01%, Cipla down 0.73%
The Indian pharmaceutical sector opened on a mixed note on April 22, 2026. The NIFTY PHARMA Index was trading at 22,403.2, down 0.2%, while the S&P BSE Healthcare Index stood…
Cipla receives two inspectional observations from USFDA at Goa facility
Cipla has announced that the United States Food and Drug Administration (USFDA) conducted an inspection at its manufacturing facility in Verna, Goa, India. The inspection, which took place from 6th…
Pharma sector stocks fall today, April 13: Biocon falls 2.35%, Cipla down 1.66%, Ajanta Pharma gains 0.77%
Pharmaceutical sector stocks traded mostly lower in early trade on Monday, April 13, 2026, with most counters under pressure. The S&P BSE Healthcare Index declined 0.88% to 42,246.47, while the…